Bitte benutzen Sie diese Referenz, um auf diese Ressource zu verweisen: doi:10.22028/D291-37725
Volltext verfügbar? / Dokumentlieferung
Titel: Neoadjuvant Chemotherapy is Not Associated with Adverse Perioperative Outcomes after Robot-Assisted Radical Cystectomy: A Case for Increased Use from the IRCC
VerfasserIn: Aldhaam, Naif A.
Elsayed, Ahmed S.
Jing, Zhe
Richstone, Lee
Wagner, Andrew A.
Rha, Koon Ho
Yuh, Bertram
Palou, Juan
Khan, Muhammad Shamim
Menon, Mani
Roupret, Morgan
Balbay, Derya
Hosseini, Abolfazl
Wiklund, Peter
Gaboardi, Franco
Maatman, Thomas J.
Mottrie, Alexandre
Wijburg, Carl
Stöckle, Michael
Hemal, Ashok
Kim, Eric
Kaouk, Jihad
Hussein, Ahmed A.
Guru, Khurshid A.
Sprache: Englisch
Titel: The Journal of Urology
Bandnummer: 203
Heft: 1
Seiten: 57-61
Verlag/Plattform: American Urological Association
Erscheinungsjahr: 2020
Freie Schlagwörter: urinary bladder
cystectomy
robotic surgical procedures
morbidity
mortality
DDC-Sachgruppe: 610 Medizin, Gesundheit
Dokumenttyp: Journalartikel / Zeitschriftenartikel
Abstract: Purpose: We sought to determine the trend of neoadjuvant chemotherapy use for nonmetastatic muscle invasive urothelial bladder cancer and whether it is associated with adverse perioperative morbidity after robot-assisted radical cystectomy. Materials and Methods: We retrospectively reviewed the IRCC (International Robotic Cystectomy Consortium) database between 2006 and 2017. After excluding patients with nonmuscle invasive bladder cancer the patients were divided into 2 groups, including those who did vs did not receive neoadjuvant chemotherapy. Data were reviewed for demographics, preoperative, operative and 90-day perioperative outcomes. We used the Cochran-Armitage trend test to assess trends of neoadjuvant chemotherapy associations with high grade and overall complications with time. Multivariate stepwise regression analyses were done to determine whether neoadjuvant chemotherapy was associated with prolonged operative time, 90-day postoperative complications, readmissions, reoperations and mortality after robot-assisted radical cystectomy. Results: A total of 298 patients (26%) received neoadjuvant chemotherapy. These patients were younger (age 67 vs 69 years, p=0.01) and more frequently had an ASA™ (American Society of Anesthesiologists™) score of 3 or greater (62% vs 55%, p=0.02) and pathological T3 stage or greater disease (28% vs 22%, p=0.04). The use of neoadjuvant chemotherapy increased significantly from 10% in 2006 to 2007 to 42% in 2016 to 2017 (p <0.01). On multivariate analysis neoadjuvant chemotherapy was not significantly associated with prolonged operative time, hospital stay, 90-day postoperative complications, reoperation or mortality. Neoadjuvant chemotherapy was associated with 90-day readmissions after robot-assisted radical cystectomy (OR 5.90, 95% CI 3.30–10.90, p <0.01). Conclusions: Neoadjuvant chemotherapy utilization has significantly increased in the last decade. It was not associated with perioperative surgical morbidity after robot-assisted radical cystectomy.
DOI der Erstveröffentlichung: 10.1097/JU.0000000000000445
URL der Erstveröffentlichung: https://www.auajournals.org/doi/10.1097/JU.0000000000000445
Link zu diesem Datensatz: urn:nbn:de:bsz:291--ds-377254
hdl:20.500.11880/34114
http://dx.doi.org/10.22028/D291-37725
ISSN: 1527-3792
0022-5347
Datum des Eintrags: 26-Okt-2022
Fakultät: M - Medizinische Fakultät
Fachrichtung: M - Urologie und Kinderurologie
Professur: M - Prof. Dr. Michael Stöckle
Sammlung:SciDok - Der Wissenschaftsserver der Universität des Saarlandes

Dateien zu diesem Datensatz:
Es gibt keine Dateien zu dieser Ressource.


Alle Ressourcen in diesem Repository sind urheberrechtlich geschützt.